Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: A randomized, double-blind, placebo-controlled study

Epilepsia

Volumn 55, Issue 3, 2014, Pages

  Stockis, Armel ^a   Watanabe, Shikiko ^a   Fauchoux, Nicolas ^b  

^a UCB PHARMA   (Belgium)

^b Technopole Atalante Villejean   (France)

Author keywords

Epilepsy; Ethinylestradiol; Levonorgestrel; Pharmacodynamics; Pharmacokinetics

Indexed keywords

BRIVARACETAM; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORGESTREL; LEVONORGESTREL; LUDEAL; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ANKLE SPRAIN; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; BLEEDING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL CYCLE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SOMNOLENCE; YOUNG ADULT;

EPILEPSY; ETHINYLESTRADIOL; LEVONORGESTREL; PHARMACODYNAMICS; PHARMACOKINETICS;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; PYRROLIDINONES; YOUNG ADULT;

EID: 84896401837     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12535     Document Type: Article

References (15)

1. Kenda BM, Matagne AC, Talaga PE, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004; 47: 530-549.
2. French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial-onset seizures. A randomized, controlled trial. Neurology 2010; 75: 519-525.
3. van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial. Epilepsia 2013; 54: 89-97.et al.
4. Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014; 55: 47-56.
5. Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br J Clin Pharmacol 2008; 66: 71-75.
6. Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 2007; 63: 680-688.
7. Sargentini-Maier ML, Espie P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 2008; 36: 36-45.
8. Stockis A, Watanabe S, Rouits E, et al. Double-blind, placebo-controlled, single and multiple rising dose study of brivaracetam in healthy Japanese male subjects-influence of CYP2C19 genotype. Epilepsy Curr 2012; 12 (Suppl. 1): 1.250. Abstract.
9. Stockis A, Rolan P,. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol 2013; 53: 1313-1321.
10. Shorvon SD, Tallis RC, Wallace HK,. Antiepileptic drugs: coprescription of proconvulsant drugs and oral contraceptives: a national study of antiepileptic drug prescribing practice. J Neurol Neurosurg Psychiatry 2002; 72: 114-115.
11. Guengerich FP,. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33: 500-508.
12. Fotherby K,. Levonorgestrel. Clinical pharmacokinetics. Clin Pharmacokinet 1995; 28: 203-215.
13. Sabers A,. Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure 2008; 17: 141-144.
14. Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009; 72: 911-914.
15. Palovaara S, Tybring G, Laine K,. The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol 2003; 56: 232-237.